Latest tweet from our researchers:

Wang T, Gautam P, Rousu J, Aittokallio T (2020)
Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
Comput Struct Biotechnol J, 18, 3819-3832
DOI 10.1016/j.csbj.2020.11.001, PubMed 33335681

Berg KCG, Brunsell TH, Sveen A, Alagaratnam S, Bjørnslett M, Hektoen M, Brudvik KW, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA (2020)
Genomic and prognostic heterogeneity among RAS/BRAF^V600E /TP53 co-mutated resectable colorectal liver metastases
Mol Oncol (in press)
DOI 10.1002/1878-0261.12885, PubMed 33325154

Lachota M, Vincenti M, Winiarska M, Boye K, Zagożdżon R, Malmberg KJ (2020)
Prospects for NK Cell Therapy of Sarcoma
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123719, PubMed 33322371

Galili B, Tekpli X, Kristensen VN, Yakhini Z (2021)
Efficient gene expression signature for a breast cancer immuno-subtype
PLoS One, 16 (1), e0245215
DOI 10.1371/journal.pone.0245215, PubMed 33434192

Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA, Hereditary Breast Cancer Clinical Study Group (2021)
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
Breast Cancer Res Treat (in press)
DOI 10.1016/j.ejca.2020.03.009, PubMed 33423179

Bergeron DE, Collins SM, Pibida L, Cessna JT, Fitzgerald R, Zimmerman BE, Ivanov P, Keightley JD, Napoli E (2020)
Ra-224 activity, half-life, and 241 keV gamma ray absolute emission intensity: A NIST-NPL bilateral comparison
Appl Radiat Isot, 170, 109572 (in press)
DOI 10.1016/j.apradiso.2020.109572, PubMed 33461017